Business
The company touts that it recently surpassed 2.5 million rings sold and has seen its member base and revenue more than double over the past year.
The Series A investment brings the company's total capital raise to $20 million.
The company will use the funds to drive adoption of its platform and provide capital infusion for expansion in the health markets.
The company will use the funds to increase the development of its computational platform to predict patient treatment responses and support drug research & development.
The funding brings the company's Series C funding round to a close and total capital raised to $155 million.
The company will use the funds to accelerate the development of its Ellipse Spinal Cord Stimulator Platform, used to treat chronic pain.
AI and automation revenue cycle management tools will be accessible to 160,000 physicians.
Tuva's CEO told MobiHealthNews that the company operates by "open-sourcing" the specialized knowledge needed to transform healthcare data and embedding that knowledge into an analytics-ready data model.
The company will fund and develop companies that focus on eight key areas in healthcare and create AI/genAI technologies that help advance those areas.
The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.